Skip to content
    Reviews

    Dynamic ctDNA-MRD in Early Breast Cancer: Subtype-Specific Implications for Surveillance and Therapy

    Jiao et alWorld journal of surgical oncology

    Circulating tumor DNA-based molecular residual disease (ctDNA-MRD) provides prognostic information in early breast cancer; however, assay detection performance and clinical interpretation vary across biological subtypes.
    In estrogen receptor (ER)-positive/HER2-negative disease, low shedding rates and the potential for late recurrence limit the negative predictive value of an isolated negative result, and the clinical utility of extended surveillance remains unproven. In HER2-positive breast cancer, rapid ctDNA clearance during neoadjuvant therapy may complement evaluations of pathological complete response and residual cancer burden, but it does not independently direct adjuvant treatment choices. In contrast, triple-negative breast cancer displays higher detectability and earlier recurrence patterns, which strengthen the relationship between persistent or re-emergent ctDNA and the risk of short-term relapse.
    Across all molecular subtypes, current evidence indicates that ctDNA-MRD should serve as an adjunct to standard clinicopathological staging and imaging rather than an independent driver of management. Standardized testing platforms and randomized intervention trials are required prior to integrating ctDNA-MRD into routine clinical practice.

    Key Takeaways

    • Across early breast cancer subtypes, ctDNA-MRD should complement clinicopathological and imaging evaluations rather than independently guide clinical treatment decisions.
    • Persistent or re-emergent ctDNA shows a stronger association with short-term relapse in triple-negative breast cancer due to higher detectability, whereas low shedding and late recurrence in ER-positive/HER2-negative disease limit the negative predictive value of a single negative test.
    Read the original sourceWorld journal of surgical oncology